NeOnc CEO Accelerates Insider Buying with $500K+ Investment Ahead of Imminent NEO100 Phase 2a Data Catalysts
CEO Amir Heshmatpour significantly increased his personal ownership by purchasing over $500,000 of NeOnc shares in recent weeks, bringing his total investment over the past year to nearly $1 million. The buying aligns with upcoming clinical milestones, specifically the interim analysis for the fully enrolled Phase 2a study of NEO100 in recurrent IDH1-mutant high-grade glioma expected later this year.
Key figures
- Insider investment recent
- $500,000
- Insider investment total ytd
- $1 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.